Diagnostic implications of p16 expression in serous papillary endometrial cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1441-1445

  Netzer, Itamar M ^a   Kerner, Hedwiga ^a   Litwin, Ludmila ^a   Lowenstein, Lior ^a   Amit, Amnon ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Biomarkers; Endometrial carcinoma; Prognosis; Serous papillary

Indexed keywords

PARAFFIN; PROTEIN P16; PROTEIN P53; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SENSIBILITY; SEROSA; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED;

AGED; CYSTADENOCARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857467696     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822eee04     Document Type: Article

References (20)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505. (Pubitemid 41111699)
3. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009;117: 693-707.
4. Weiderpass E, Persson I, Adami HO, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11:185-192. (Pubitemid 30088399)
5. Ludwig H. Prognostic factors in endometrial cancer. Int J Gynaecol Obstet. 1995;49:S1-S7.
6. Fader A, Boruta D, Olawaiye AB, et al. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22:21-29.
7. Yemelyanova A, Ji H, Shih IeM J, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas. Am J Surg Pathol. 2009;33:1504-1514.
8. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 2002;110:673-689. (Pubitemid 36005834)
9. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365. (Pubitemid 32467045)
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
11. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol. 1995;6:63-72.
12. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411-432.
13. Ignatov A, Bischoff J, Schwarzenau C, et al. p16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol. 2008;111:365-371.
14. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res. 2000;6:153-159. (Pubitemid 30064988)
15. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333. (Pubitemid 46986071)
16. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100. (Pubitemid 44106724)
17. Karamitopoulou E, Zlobec I, Koumarianou A, et al. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases. Cancer. 2010;116:4474-4486.
18. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010;34:1088-1096.
19. Grendys EC Jr, Blessing JA, Burger R, et al. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;98:249-253. (Pubitemid 41019113)
20. Wang LM, Ren DM. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem. 2010;10:1058-1070.